MRES corporate history...for those that like the detail..
CORPORATE BACKGROUND
The Company was created through articles of amalgamation filed pursuant to the provisions of the Business Corporations Act (Ontario) 1990, on September 21, 1995, upon the amalgamation of two predecessor companies, Winteroad Resources Limited and PenStar Wirecom, Ltd.
On December 10, 1997, the Company became the subject of a reverse takeover by two Canadian companies, Neuro-Biotech Inc. ("NBI") and 1246895 Ontario Inc., and changed its name to Neuro-Biotech Corporation. On April 27, 1998, Neuro-Biotech's common shares began trading on the Canadian Dealing Network under the symbol, "NBIO."
The executive offices of the Company are located at 1020 Route de l'Eglise, Suite 600, Sainte-Foy, Quebec, G1V 3V9.
NEURO-BIOTECH INC.
NBI is the Company's operating subsidiary. NBI was founded to capitalize upon the technological base that had been established by its founder, Dr. Andree G. Roberge. Dr. Roberge conducted research at Laval University for over 20 years, focusing on stress mechanisms, with particular emphasis on the relationship between the brain and the whole body. During that period, Dr. Roberge, using a series of therapeutic molecules, developed kits that could aid in increasing the health and well-being of individuals suffering from stress-related and neuroscience-based diseases.
In 1979, Dr. Roberge was invited by the National Research Council of Canada to participate in a study on the mechanisms related to stress after cold exposure. Soon after this study, Dr. Roberge focused on the mechanisms involving the HPAS axis. This research provided the scientific foundation for Neuro-Biotech.
In 1982, Dr. Roberge developed a neurochemical experimental model for neurologic diseases, including Alzheimer's and Schizophrenia. By 1985, Dr. Roberge had characterized a bio-indicator and started to develop a new diagnostic tool to measure stress levels. This breakthrough served as the basis for Neuro-Biotech's first diagnostic kit, SymPath-TM-. In 1986, pre-clinical studies began for the Company's first three diagnostics kits.
In 1988, Logilab Inc. ("Logilab") was formed to concretely develop and commercialize the results of the research done by Dr. Roberge at Laval University. Logilab was incorporated under Part 1A of the Companies Act (Quebec) by articles of incorporation dated November 22, 1988. By articles of amendment dated July 23, 1996, Logilab changed its corporate name to Neuro-Biotech Inc.
2
20FR12G 8th Page of 81 TOC 1st Previous Next Bottom Just 8th
In 1997, NBI acquired the intellectual property related to its diagnostic kit technology platform from Laval University for the amount of $3,000,000 payable in the form of a royalty at a rate of 3.5% of the Company's gross sales revenues, with no specified due date.
